Featured Publications
Illusory generalizability of clinical prediction models
Chekroud A, Hawrilenko M, Loho H, Bondar J, Gueorguieva R, Hasan A, Kambeitz J, Corlett P, Koutsouleris N, Krumholz H, Krystal J, Paulus M. Illusory generalizability of clinical prediction models. Science 2024, 383: 164-167. PMID: 38207039, DOI: 10.1126/science.adg8538.Peer-Reviewed Original ResearchLongitudinal Trajectories of Multiple Nicotine Product Use Among Youths in the Population Assessment of Tobacco and Health Study
Simon P, Jiang Y, Buta E, Sartor CE, Krishnan-Sarin S, Gueorguieva R. Longitudinal Trajectories of Multiple Nicotine Product Use Among Youths in the Population Assessment of Tobacco and Health Study. JAMA Network Open 2022, 5: e223549. PMID: 35319763, PMCID: PMC8943628, DOI: 10.1001/jamanetworkopen.2022.3549.Peer-Reviewed Original ResearchConceptsNicotine product useCigar useTobacco usersTobacco useHealth StudyCigarette useProduct useWave 1Significant public health concernLongitudinal trajectoriesPublic health concernNon-Hispanic whitesTobacco product useLogistic regression modelsTobacco use behaviorsComplex survey designMultinomial logistic regression modelsDays of useSocioecological factorsMAIN OUTCOMESmokeless tobaccoLower oddsNicotine productsLatent class growth analysisSociodemographic factorsTrajectories of relapse in randomised, placebo-controlled trials of treatment discontinuation in major depressive disorder: an individual patient-level data meta-analysis
Gueorguieva R, Chekroud AM, Krystal JH. Trajectories of relapse in randomised, placebo-controlled trials of treatment discontinuation in major depressive disorder: an individual patient-level data meta-analysis. The Lancet Psychiatry 2017, 4: 230-237. PMID: 28189575, PMCID: PMC5340978, DOI: 10.1016/s2215-0366(17)30038-x.Peer-Reviewed Original ResearchConceptsActive medicationActive treatmentClinical trialsDepression severityHamilton Depression Rating Scale scoresDepression Rating Scale scoresClinical Global Impression scoresIndividual patient-level dataDouble-blind treatmentPlacebo-controlled trialPatterns of relapseGlobal Impression scoresIndividual patient dataPrevention of relapseTrajectory class membershipTreatment of depressionMajor depressive disorderRating Scale scoresPatient-level dataPost-traumatic stress disorderTreatment discontinuationAntidepressant treatmentClinical responseAlcohol Research CenterAntidepressant medicationTemporal patterns of adherence to medications and behavioral treatment and their relationship to patient characteristics and treatment response
Gueorguieva R, Wu R, Krystal JH, Donovan D, O'Malley SS. Temporal patterns of adherence to medications and behavioral treatment and their relationship to patient characteristics and treatment response. Addictive Behaviors 2013, 38: 2119-2127. PMID: 23435273, PMCID: PMC3595348, DOI: 10.1016/j.addbeh.2013.01.024.Peer-Reviewed Original ResearchConceptsPercent heavy drinking daysAdherence trajectoriesExcellent adherersPercent days abstinentPatient characteristicsMedication adherenceTreatment outcomesMedication adherence trajectoriesPatterns of treatmentHeavy drinking daysPatterns of adherenceExcellent medication adherenceLack of benefitTrajectories of adherenceIntervention main effectsActive medicationAdverse eventsPharmacologic treatmentHigher percent days abstinentTreatment adherenceTreatment modalitiesWorse outcomesTreatment responseDays abstinentDrinking daysJoint Modelling of Longitudinal Outcome and Interval-Censored Competing Risk Dropout in a Schizophrenia Clinical Trial
Gueorguieva R, Rosenheck R, Lin H. Joint Modelling of Longitudinal Outcome and Interval-Censored Competing Risk Dropout in a Schizophrenia Clinical Trial. Journal Of The Royal Statistical Society Series A (Statistics In Society) 2011, 175: 417-433. PMID: 22468033, PMCID: PMC3315284, DOI: 10.1111/j.1467-985x.2011.00719.x.Peer-Reviewed Original ResearchLongitudinal outcomesClinical Antipsychotic TrialsQuality of lifeSchizophrenia clinical trialsStudy medicationAntipsychotic medicationClinical trialsAntipsychotic TrialsStudy participantsPhase IIntervention effectivenessMedicationsSignificant differencesSelection biasTrialsOutcomesJoint modelling approachCauses of dropoutLarge percentageParticipantsTolerabilityPatientsOutcome valuesEffect of dropoutStudy scheduleJoint analysis of repeatedly observed continuous and ordinal measures of disease severity
Gueorguieva RV, Sanacora G. Joint analysis of repeatedly observed continuous and ordinal measures of disease severity. Statistics In Medicine 2006, 25: 1307-1322. PMID: 16217846, DOI: 10.1002/sim.2270.Peer-Reviewed Original ResearchMove Over ANOVA: Progress in Analyzing Repeated-Measures Data andIts Reflection in Papers Published in the Archives of General Psychiatry
Gueorguieva R, Krystal JH. Move Over ANOVA: Progress in Analyzing Repeated-Measures Data andIts Reflection in Papers Published in the Archives of General Psychiatry. JAMA Psychiatry 2004, 61: 310-317. PMID: 14993119, DOI: 10.1001/archpsyc.61.3.310.Peer-Reviewed Original ResearchA Correlated Probit Model for Joint Modeling of Clustered Binary and Continuous Responses
Gueorguieva R, Agresti A. A Correlated Probit Model for Joint Modeling of Clustered Binary and Continuous Responses. Journal Of The American Statistical Association 2001, 96: 1102-1112. DOI: 10.1198/016214501753208762.Peer-Reviewed Original ResearchStatistical Methods in Psychiatry and Related Fields: Longitudinal, Clustered and Other Repeated Measures Data.
Gueorguieva R. (2017). Chapman & Hall/CRC Interdisciplinary Statistics series. ISBN 9781498740760.Peer-Reviewed Original ResearchCross-trial prediction of treatment outcome in depression: a machine learning approach
Chekroud AM, Zotti RJ, Shehzad Z, Gueorguieva R, Johnson MK, Trivedi MH, Cannon TD, Krystal JH, Corlett PR. Cross-trial prediction of treatment outcome in depression: a machine learning approach. The Lancet Psychiatry 2016, 3: 243-250. PMID: 26803397, DOI: 10.1016/s2215-0366(15)00471-x.Peer-Reviewed Original ResearchConceptsTreatment outcomesTreatment groupsEscitalopram treatment groupSpecific antidepressantsPatient-reported dataSequenced Treatment AlternativesClinical trial dataIndependent clinical trialsClinical remissionSymptomatic remissionClinical trialsTreatment efficacyPatientsProspective identificationTreatment alternativesTrial dataDepressionRemissionAntidepressantsOutcomesGroupLevel 1CitalopramCohortClinicians
2024
Cognitive Behavioral Therapy and Lisdexamfetamine, Alone and Combined, for Binge-Eating Disorder With Obesity: A Randomized Controlled Trial.
Grilo C, Ivezaj V, Tek C, Yurkow S, Wiedemann A, Gueorguieva R. Cognitive Behavioral Therapy and Lisdexamfetamine, Alone and Combined, for Binge-Eating Disorder With Obesity: A Randomized Controlled Trial. American Journal Of Psychiatry 2024 PMID: 39659158, DOI: 10.1176/appi.ajp.20230982.Peer-Reviewed Original ResearchCognitive-behavioral therapyBinge-eating disorderEffectiveness of cognitive-behavioral therapyBinge-eating remission ratesEating-disorder psychopathologyCognitive behavioral therapyEvidence-based treatmentsRemission ratePercent weight lossHigher remission ratesBinge-eating frequencyBehavioral therapyPosttreatment assessmentLisdexamfetamineRandomized controlled trialsHeightened ratesCostly public health problemIntention-to-treat ratesFunctional impairmentWeight lossControlled trialsDisordersPosttreatmentIndividualized treatmentMixed modelsBrief Cognitive Behavioral Therapy for Suicidal Inpatients
Diefenbach G, Lord K, Stubbing J, Rudd M, Levy H, Worden B, Sain K, Bimstein J, Rice T, Everhardt K, Gueorguieva R, Tolin D. Brief Cognitive Behavioral Therapy for Suicidal Inpatients. JAMA Psychiatry 2024, 81: 1177-1186. PMID: 39259550, PMCID: PMC11391362, DOI: 10.1001/jamapsychiatry.2024.2349.Peer-Reviewed Original ResearchBrief cognitive behavioral therapyCognitive behavioral therapySubstance use disordersSuicidal ideationBehavioral therapySuicide attemptsFollow-up assessmentUse disorderOccurrence of suicide attemptsPsychiatric readmissionRates of psychiatric readmissionSuicide prevention treatmentsEffect of treatment conditionPrivate psychiatric hospitalTreatment effectsSuicidal inpatientsSuicide riskSuicidal crisisPsychiatric hospitalIndividual sessionsIdeationSuicide reattemptsPost hoc analysisSelf-reportBlinded interviewersLisdexamfetamine maintenance treatment for binge-eating disorder following successful treatments: randomized double-blind placebo-controlled trial
Grilo C, Ivezaj V, Yurkow S, Tek C, Wiedemann A, Gueorguieva R. Lisdexamfetamine maintenance treatment for binge-eating disorder following successful treatments: randomized double-blind placebo-controlled trial. Psychological Medicine 2024, 54: 3334-3344. PMID: 39258475, PMCID: PMC11496227, DOI: 10.1017/s003329172400148x.Peer-Reviewed Original ResearchEating-disorder psychopathologyBinge-eating disorderMaintenance treatmentAcute treatmentBinge-eating remission ratesCognitive-behavioral therapyEfficacy of lisdexamfetamineSignificant weight gainDouble-blind placebo-controlled trialAcute respondersLisdexamfetamine treatmentPsychopathological outcomesPosttreatment assessmentLisdexamfetaminePlacebo-controlled trialRandomized double-blind placebo-controlled trialSingle-site trialAssociated with significant weight lossPsychopathologyBinge-eatingRemission rateWeight lossPlaceboRelapse rateControl researchEfficacy and tolerability of antipsychotic polypharmacy for schizophrenia spectrum disorders. A systematic review and meta-analysis of individual patient data
Lochmann van Bennekom M, IntHout J, Gijsman H, Akdede B, Yağcıoğlu A, Barnes T, Galling B, Gueorguieva R, Kasper S, Kreinin A, Nielsen J, Nielsen R, Remington G, Repo-Tiihonen E, Schmidt-Kraepelin C, Shafti S, Xiao L, Correll C, Verkes R. Efficacy and tolerability of antipsychotic polypharmacy for schizophrenia spectrum disorders. A systematic review and meta-analysis of individual patient data. Schizophrenia Research 2024, 272: 1-11. PMID: 39142215, DOI: 10.1016/j.schres.2024.07.035.Peer-Reviewed Original ResearchClinical Global Impression ScaleSchizophrenia spectrum disordersPositive and Negative Syndrome ScaleBaseline PANSS total scoreAntipsychotic polypharmacyPANSS total scoreTotal scorePositive symptomsPsychotic patientsPositive and Negative Syndrome Scale positive symptom subscaleNegative symptom subscale scoreSubgroup of psychotic patientsBaseline positive symptomsExtrapyramidal side effectsNegative Syndrome ScalePositive symptom subscaleSecond-generation antipsychoticsGlobal Impression ScaleModerators of efficacySeverely psychotic patientsStudy-level moderatorsStudy discontinuationSymptom subscale scoresAntipsychotic monotherapySyndrome ScalePulsed nicotine infusions as a model for smoking: validating a tool to explore nicotine thresholds in humans
Parida S, MacLean R, Gueorguieva R, Sofuoglu M. Pulsed nicotine infusions as a model for smoking: validating a tool to explore nicotine thresholds in humans. Psychopharmacology 2024, 241: 1915-1922. PMID: 38970644, DOI: 10.1007/s00213-024-06609-6.Peer-Reviewed Original ResearchDiscriminative stimulus effectsAddiction thresholdNicotine doseDiscriminative stimulus effects of nicotineStimulus effects of nicotineNicotine deliveryEffects of nicotineOvernight abstinenceStimulus effectsNicotine infusionSubjective effectsTest sessionsNicotineMethodsEleven participantsInfusion procedureLow dosesParticipantsThreshold doseConclusionsTheseAbstinenceDoseHeart rateInfusionSmokingObjectivesToEXAMINING RACIAL DIFFERENCES IN SMOKING-RELATED OUTCOMES IN HUMANS DURING EARLY ABSTINENCE AND AFTER INTRAVENOUS NICOTINE INFUSION
Schwartz E, Palmisano A, Gueorguieva R, DeVito E, Sofuoglu M. EXAMINING RACIAL DIFFERENCES IN SMOKING-RELATED OUTCOMES IN HUMANS DURING EARLY ABSTINENCE AND AFTER INTRAVENOUS NICOTINE INFUSION. Drug And Alcohol Dependence 2024, 260: 110027. DOI: 10.1016/j.drugalcdep.2023.110027.Peer-Reviewed Original ResearchADVANCED CHARACTERIZATION OF ON- ELECTROCARDIOGRAPHIC (ECG) SENSORS’ DISCRIMINATORY POWER IN A HUMAN LABORATORY COCAINE SELF-ADMINISTRATION (SA) PARADIGM
Angarita G, Mayerson T, Pittman B, Nararajan A, Parate A, Marlin B, Gueorguieva R, Potenza M, Ganesan D, Malison R. ADVANCED CHARACTERIZATION OF ON- ELECTROCARDIOGRAPHIC (ECG) SENSORS’ DISCRIMINATORY POWER IN A HUMAN LABORATORY COCAINE SELF-ADMINISTRATION (SA) PARADIGM. Drug And Alcohol Dependence 2024, 260: 110014. DOI: 10.1016/j.drugalcdep.2023.110014.Peer-Reviewed Original ResearchSmartband-based smoking detection and real-time brief mindfulness intervention: findings from a feasibility clinical trial
Horvath M, Pittman B, O’Malley S, Grutman A, Khan N, Gueorguieva R, Brewer J, Garrison K. Smartband-based smoking detection and real-time brief mindfulness intervention: findings from a feasibility clinical trial. Annals Of Medicine 2024, 56: 2352803. PMID: 38823419, PMCID: PMC11146247, DOI: 10.1080/07853890.2024.2352803.Peer-Reviewed Original ResearchConceptsBrief mindfulness interventionsMindfulness exercisesTreatment startersMindfulness interventionSmoking interventionsOnline mindfulness trainingWhite non-HispanicMindfulness trainingTreatment fidelityFeasibility measuresHelpfulness ratingsNon-HispanicDaily smokersPredicting smokingReduce smokingExerciseSmokingCigarette smokingInterventionLow completenessAdherenceParticipantsSmartbandAcceptanceMindfulnessBehavioral Precursors of Nicotine Product Use Trajectories Among Youth
Buta E, Gueorguieva R, Simon P, Garrison K. Behavioral Precursors of Nicotine Product Use Trajectories Among Youth. American Journal Of Preventive Medicine 2024, 67: 360-369. PMID: 38782105, DOI: 10.1016/j.amepre.2024.05.009.Peer-Reviewed Original ResearchNicotine useNicotine productsHarm perceptionsPopulation Assessment of Tobacco and Health StudyBehavioral precursorsPublic health priorityNon-user classPriority intervention targetsPredictors of trajectoriesNonuser classesHealth StudyHealth priorityNicotineHigher oddsCentral network nodesYouth agesNon-usersOddsIntervention targetsPopulation AssessmentYouthPositive expectationsSocioecological factors associated with multiple nicotine product use among U.S. youth: Findings from the population assessment of tobacco and health (PATH) study 2013–2018
Simon P, Stefanovics E, Ying S, Gueorguieva R, Krishnan-Sarin S, Buta E. Socioecological factors associated with multiple nicotine product use among U.S. youth: Findings from the population assessment of tobacco and health (PATH) study 2013–2018. Preventive Medicine 2024, 183: 107956. PMID: 38615947, DOI: 10.1016/j.ypmed.2024.107956.Peer-Reviewed Original ResearchPopulation Assessment of Tobacco and HealthNicotine product useU.S. youthAssociated with tobacco useEstimate adjusted associationsPopulation AssessmentPromote harm reductionTobacco product useMultinomial logistic regressionTobacco useAdjusted associationsSocioecological approachStudy Wave 1Harm reductionProduct useIntrapersonal factorsLogistic regressionWave 1Family factorsLifetime historyNicotine productsOlder ageLifetime usersYouthPrevent escalation